Hanson & Doremus Investment Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.12M | Sell |
5,916
-93
| -2% | -$17.5K | 0.11% | 91 |
|
|
2026
Q1 | $1.19M | Sell |
6,009
-196
| -3% | -$37.8K | 0.14% | 86 |
|
|
2025
Q4 | $1.14M | Sell |
6,205
-211
| -3% | -$37K | 0.14% | 80 |
|
|
2025
Q3 | $984K | Sell |
6,416
-743
| -10% | -$112K | 0.12% | 82 |
|
|
2025
Q2 | $1M | Sell |
7,159
-17
| -0.2% | -$2.38K | 0.13% | 81 |
|
|
2025
Q1 | $1.05M | Sell |
7,176
-70
| -1% | -$10.1K | 0.15% | 79 |
|
|
2024
Q4 | $949K | Sell |
7,246
-65
| -0.9% | -$9.1K | 0.15% | 77 |
|
|
2024
Q3 | $1.14M | Sell |
7,311
-181
| -2% | -$29.2K | 0.18% | 70 |
|
|
2024
Q2 | $1.17M | Hold |
7,492
| – | – | 0.2% | 69 |
|
|
2024
Q1 | $1.01M | Sell |
7,492
-113
| -1% | -$15K | 0.17% | 73 |
|
|
2023
Q4 | $1.02M | Sell |
7,605
-119
| -2% | -$15.5K | 0.19% | 75 |
|
|
2023
Q3 | $1.05M | Sell |
7,724
-298
| -4% | -$40.7K | 0.22% | 77 |
|
|
2023
Q2 | $1.15M | Sell |
8,022
-189
| -2% | -$27.8K | 0.24% | 75 |
|
|
2023
Q1 | $1.14M | Sell |
8,211
-146
| -2% | -$19.6K | 0.25% | 74 |
|
|
2022
Q4 | $1.13M | Sell |
8,357
-403
| -5% | -$50.5K | 0.24% | 76 |
|
|
2022
Q3 | $961K | Sell |
8,760
-283
| -3% | -$35.9K | 0.25% | 77 |
|
|
2022
Q2 | $1.2M | Sell |
9,043
-1,440
| -14% | -$189K | 0.29% | 68 |
|
|
2022
Q1 | $1.39M | Sell |
10,483
-571
| -5% | -$68.5K | 0.3% | 67 |
|
|
2021
Q4 | $1.29M | Sell |
11,054
-77
| -0.7% | -$9.06K | 0.28% | 67 |
|
|
2021
Q3 | $1.34M | Sell |
11,131
-1,159
| -9% | -$135K | 0.31% | 66 |
|
|
2021
Q2 | $1.35M | Buy |
12,290
+219
| +2% | +$24K | 0.4% | 51 |
|
|
2021
Q1 | $1.2M | Buy |
12,071
+10
| +0.1% | +$1K | 0.28% | 79 |
|
|
2020
Q4 | $1.21M | Sell |
12,061
-229
| -2% | -$24.3K | 0.3% | 66 |
|
|
2020
Q3 | $1.35M | Sell |
12,290
-699
| -5% | -$77.7K | 0.4% | 51 |
|
|
2020
Q2 | $1.37M | Sell |
12,989
-539
| -4% | -$55.7K | 0.44% | 45 |
|
|
2020
Q1 | $1.21M | Sell |
13,528
-1,014
| -7% | -$95.5K | 0.41% | 50 |
|
|
2019
Q4 | $1.45M | Sell |
14,542
-357
| -2% | -$33.6K | 0.42% | 55 |
|
|
2019
Q3 | $1.33M | Sell |
14,899
-740
| -5% | -$64.2K | 0.41% | 54 |
|
|
2019
Q2 | $1.29M | Sell |
15,639
-475
| -3% | -$37.2K | 0.41% | 54 |
|
|
2019
Q1 | $1.3M | Buy |
16,114
+47
| +0.3% | +$3.71K | 0.43% | 55 |
|
|
2018
Q4 | $1.22M | Sell |
16,067
-1,106
| -6% | -$86.4K | 0.44% | 52 |
|
|
2018
Q3 | $1.36M | Sell |
17,173
-58
| -0.3% | -$4.39K | 0.43% | 57 |
|
|
2018
Q2 | $1.21M | Sell |
17,231
-685
| -4% | -$49.3K | 0.4% | 64 |
|
|
2018
Q1 | $1.25M | Buy |
17,916
+1,436
| +9% | +$99.5K | 0.39% | 62 |
|
|
2017
Q4 | $1.14M | Hold |
16,480
| – | – | 0.38% | 70 |
|
|
2017
Q3 | $1.12M | Sell |
16,480
-138
| -0.8% | -$8.72K | 0.39% | 70 |
|
|
2017
Q2 | $1.13M | Buy |
16,618
+143
| +0.9% | +$9.34K | 0.42% | 67 |
|
|
2017
Q1 | $1.03M | Buy |
16,475
+601
| +4% | +$35K | 0.41% | 68 |
|
|
2016
Q4 | $867K | Sell |
15,874
-309
| -2% | -$17.5K | 0.37% | 77 |
|
|
2016
Q3 | $1.06M | Sell |
16,183
-322
| -2% | -$21K | 0.49% | 62 |
|
|
2016
Q2 | $997K | Sell |
16,505
-325
| -2% | -$18.9K | 0.45% | 63 |
|
|
2016
Q1 | $948K | Sell |
16,830
-190
| -1% | -$11.4K | 0.43% | 67 |
|
|
2015
Q4 | $1.16M | Hold |
17,020
| – | – | 0.52% | 52 |
|
|
2015
Q3 | $1.08M | Sell |
17,020
-1,250
| -7% | -$82.2K | 0.52% | 53 |
|
|
2015
Q2 | $1.16M | Sell |
18,270
-105
| -0.6% | -$7.19K | 0.5% | 60 |
|
|
2015
Q1 | $1.26M | Sell |
18,375
-80
| -0.4% | -$5.56K | 0.53% | 55 |
|
|
2014
Q4 | $1.3M | Hold |
18,455
| – | – | 0.56% | 54 |
|
|
2014
Q3 | $1.32M | Sell |
18,455
-100
| -0.5% | -$7.32K | 0.6% | 51 |
|
|
2014
Q2 | $1.38M | Hold |
18,555
| – | – | 0.63% | 49 |
|
|
2014
Q1 | $1.2M | Hold |
18,555
| – | – | 0.57% | 54 |
|
|
2013
Q4 | $1.1M | Buy |
18,555
+2,485
| +15% | +$135K | 0.53% | 58 |
|
|
2013
Q3 | $835K | Buy |
16,070
+4,515
| +39% | +$227K | 0.42% | 78 |
|
|
2013
Q2 | $547K | Buy |
+11,555
| New | +$588K | 0.3% | 94 |
|
Other funds holding AZN
EP
IA
Hanson & Doremus Investment Management's AZN Position: Q2 2026 in Review
Hanson & Doremus Investment Management reduced its AstraZeneca (AZN) stake by 1.5% in Q2 2026, selling an estimated $17.5K and leaving 5,916 shares worth $1.12M. The position accounts for 0.11% of the portfolio, ranked #91.
Hanson & Doremus Investment Management first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.45M in Q4 2019. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Hanson & Doremus Investment Management held 5,916 shares of AstraZeneca worth $1.12M as of Q2 2026.
- Hanson & Doremus Investment Management sold 93 AstraZeneca shares in Q2 2026, an estimated $17.5K.
- AstraZeneca made up 0.11% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #91 holding.
- Hanson & Doremus Investment Management first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
- Hanson & Doremus Investment Management's AstraZeneca position peaked at $1.45M in Q4 2019.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.